Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors at 10 institutions in 1 country.
Xu Hua *Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9775-4129
Yongsheng Li *Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-1914-0727
Sairahul R Pentaparthi *Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-1038-0206
Daniel J McGrail *Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6669-6069
Raymond Zou *Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4059-5155
Li Guo *Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5624-5259
Aditya ShrawatCollege of Natural Sciences, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-6115-552X
Kara M CirilloDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9040-0352
Qing LiDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1108-6562
Akshay BhatLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-3205-1761
Min XuNeuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas.ORCID 0000-0001-8245-4695
Dan QiNeuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas.ORCID 0000-0001-7015-1849
Ashok SinghDell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0001-6498-0018
Francis McGrathDell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-2886-9889
Steven AndrewsDell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-4797-4032
Kyaw Lwin AungLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0001-9889-0379
Jishnu DasCenter for Systems Immunology, Department of Immunology, and Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-5747-064X
Yunyun ZhouChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0003-1689-8575
Alessia LodiDepartment of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-2104-5713
Gordon B MillsDepartment of Cell, Developmental and Cancer Biology, School of Medicine, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-0144-9614
S Gail EckhardtLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-8103-1620
Marc L MendilloDepartment of Biochemistry and Molecular Genetics, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.ORCID 0000-0001-8128-0128
Stefano TizianiLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-7230-0307
Erxi WuLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0002-1680-3639
Jason H HuangNeuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas.ORCID 0000-0002-4426-0168
Nidhi SahniDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9155-5882
S Stephen YiLivestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.ORCID 0000-0003-0047-8103
Livestrong Foundation · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas at Austin · USAustin College · USBaylor Scott & White Medical Center - Temple · USChildren's Hospital of Philadelphia · USOregon Health & Science University · USRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityTemple College · USUniversity of Pittsburgh · US
Funding
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9M
Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6M
Systematic Characterization and Targeting of Neomorphic Drivers in CancerU01CA281902 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Benjamin Deneen, Han Liang · 2023 to 2026
$3.5M
Network-based Framework to Decode Novel Gain-of-Function Mutations and their Mechanistic Roles in General Human DiseasesR35GM133658 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI S. Stephen Yi · 2019 to 2026
$2.6M
Deciphering Functional Consequences of Specific and Combinatorial Mutations in Protein Interaction NetworksR35GM137836 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SAHNI, NIDHI · 2020 to 2023
$1.8M
Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy OutcomesK99CA240689 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCGRAIL, DANIEL JAMES · 2019 to 2020
Somatic mutations are a major source of cancer development, and many driver mutations have been identified in protein coding regions. However, the function of mutations located in miRNA and their target binding sites throughout the human genome remains largely unknown. Here, we built detailed cancer-specific miRNA regulatory networks across 30 cancer types to systematically analyze the effect of mutations in miRNAs and their target sites in 3' untranslated region (3' UTR), coding sequence (CDS), and 5' UTR regions. A total of 3,518,261 mutations from 9,819 samples were mapped to miRNA-gene interactions (mGI). Mutations in miRNAs showed a mutually exclusive pattern with mutations in their target genes in almost all cancer types. A linear regression method identified 148 candidate driver mutations that can significantly perturb miRNA regulatory networks. Driver mutations in 3'UTRs played their roles by altering RNA binding energy and the expression of target genes. Finally, mutated driver gene targets in 3' UTRs were significantly downregulated in cancer and functioned as tumor suppressors during cancer progression, suggesting potential miRNA candidates with significant clinical implications. A user-friendly, open-access web portal (mGI-map) was developed to facilitate further use of this data resource. Together, these results will facilitate novel noncoding biomarker identification and therapeutic drug design targeting the miRNA regulatory networks. SIGNIFICANCE: A detailed miRNA-gene interaction map reveals extensive miRNA-mediated gene regulatory networks with mutation-induced perturbations across multiple cancers, serving as a resource for noncoding biomarker discovery and drug development.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer. · full record | OpenQuestion